Zusammenfassung
Diese Einschätzung wurde am 17.10.18 mit einem Endkurs von 1,16 € beendet. Aufwärts ging es für die BUY Einschätzung von Quitte mit einer Rendite von 13,16 %. Quitte hat 50% Zuversicht bei dieser Einschätzung
Finanztrends
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Vical Inc | - | - | - | - |
| iShares Core DAX® | 0.444% | 3.030% | 12.677% | 49.790% |
| iShares Nasdaq 100 | 3.819% | 4.073% | 33.152% | 88.253% |
| iShares Nikkei 225® | 1.148% | 6.904% | 45.488% | 61.922% |
| iShares S&P 500 | 2.371% | 2.677% | 25.689% | 63.539% |
Kommentare von Quitte zu dieser Einschätzung
In der Diskussion Vical Inc diskutieren
Zock auf failed
In a press release issued early this morning, the company announced top-line results from its Phase 2 clinical study of bivalent. Bivalent was designed as a candidate for the treatment of herpes simplex virus type 2 (HSV-2). Unfortunately, the study did not meet its primary enpdoint of annualized lesion recurrence rate. This endpoint was calculated based on those genital recurrences that were both clincially- and virologically-confirmed during a minimum of nine months of surveillance.
https://seekingalpha.com/article/4181071-vical-compelling-reason-buy
(Vom Mitglied beendet)